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Background: Advances in HCT strategies have led to an incremental improvement in survival of 10% per decade. Focus has now shifted to the 
quality of survival. HCT survivors are at increased risk of chronic health conditions, including CHF.
Methods: Using a nested case-control design, individuals diagnosed with CHF within the first two years following HCT (early) or ≥ 2 years after 
HCT (late) were identified from a cohort of 3,368 long-term HCT survivors transplanted between 1981 and 2006, and matched with controls (HCT 
survivors without CHF) on: age and year of HCT, type of HCT (allogeneic v autologous), and length of follow-up. Variables examined included: host 
demographics, pre-transplant therapeutic exposures, HCT-conditioning, and comorbidities (diabetes, hypertension, dyslipidemia).
Results: One hundred cases with CHF were identified (47 early, 53 late); mean age at HCT: 47.6 yrs (16.3-71.0); mean time to CHF: 3.1 yr (0.02-
18.9); 74% received autologous HCT. Mean ejection fraction (method of disc): 36.8% (13-53%). All had clinical CHF. Compared to controls (N=277), 
cases were more likely to be female (57% v 43%; p=0.02), had greater BMI at HCT (27.8 v 26.1 kg/m2; p=0.01), and were more likely to have 
multiple (≥2) comorbidities after HCT (23.0% v 12.6%, p<0.01). Pre-HCT mediastinal radiation (XRT), high dose (HD) anthracycline (≥250 mg/m2) 
without XRT, and HD-anthracycline with XRT was associated with incremental increase in odds ratio (OR) = 2.4, 3.8, and 7.4, respectively; p<0.01). 
Stratified multivariate analyses by onset of CHF (early, late) revealed the following: HD-anthracycline alone (OR 3.0; p=0.03) and HD anthracycline 
with XRT (OR 8.1; p=0.04) to be independently associated with risk of early-CHF; while presence of multiple comorbidities (OR: 3.8; p<0.01) 
significantly increased risk of late-onset CHF. Overall survival following CHF was 49% at 5 yrs.
Conclusion: Pre-HCT therapeutic exposures (anthracyclines and XRT) are primarily associated with risk of early-onset CHF; while post-HCT 
comorbidities are responsible for late-onset CHF. These data form the basis for targeted surveillance as well as intervention following HCT in the form 
of aggressive management of comorbidities.
